Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety Surveillance Peter Arlett Commentary Open access 13 January 2019 Pages: 581 - 582
From Data Silos to Standardized, Linked, and FAIR Data for Pharmacovigilance: Current Advances and Challenges with Observational Healthcare Data Vassilis Koutkias Commentary 22 January 2019 Pages: 583 - 586
Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Anthony SteinJanet L. FranklinGuiandre Joseph Review Article Open access 18 December 2018 Pages: 587 - 601
Benefit–Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation Philip B. Miner Jr. Review Article 16 January 2019 Pages: 603 - 615
Benefit–Risk Assessment of Vedolizumab in the Treatment of Crohn’s Disease and Ulcerative Colitis Robert BattatChristopher MaBrian G. Feagan Review Article 04 March 2019 Pages: 617 - 632
Managing Risks with Immune Therapies in Multiple Sclerosis Moritz FörsterPatrick KüryDavid Kremer Review Article 03 January 2019 Pages: 633 - 647
Evaluation of Postmarketing Reports from Industry-Sponsored Programs in Drug Safety Surveillance Lisa HarinsteinDipti KalraGerald J. Dal Pan Original Research Article 19 December 2018 Pages: 649 - 655
Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance Suehyun LeeJongsoo HanJu Han Kim Original Research Article 16 January 2019 Pages: 657 - 670
Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database: Trends and Specific Signals from a Disproportionality Analysis Khac-Dung NguyenHoang-Anh NguyenHaleh Bagheri Original Research Article 27 November 2018 Pages: 671 - 682
Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives Janet SultanaUgo MorettiRoberto Leone Meeting Report 18 December 2018 Pages: 683 - 687
Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ Between 2014 and 2017’ Philip Schaffalitzky de MuckadellClaes Christian Strom Letter to the Editor Open access 01 April 2019 Pages: 689 - 691
Authors’ reply to Schaffalitzky de Muckadell and colleague’s Comment on “Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017” Birgit EhlkenLennart NathellStefan Wohlfeil Letter to the Editor Open access 01 April 2019 Pages: 693 - 696
Correction to: Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice S. Jill StocksEvangelos KontopantelisDarren M. Ashcroft Correction Open access 08 April 2019 Pages: 697 - 697